Halozyme Therapeutics, Inc. (HALO)
Automate Your Wheel Strategy on HALO
With Tiblio's Option Bot, you can configure your own wheel strategy including HALO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HALO
- Rev/Share 8.8001
- Book/Share 3.9141
- PB 14.3253
- Debt/Equity 3.1257
- CurrentRatio 8.3923
- ROIC 0.2343
- MktCap 6909001470.0
- FreeCF/Share 4.0235
- PFCF 13.9363
- PE 14.234
- Debt/Assets 0.6863
- DivYield 0
- ROE 1.2224
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HALO | Morgan Stanley | Overweight | Equal Weight | -- | $62 | May 14, 2025 |
| Downgrade | HALO | Leerink Partners | Market Perform | Underperform | -- | $47 | May 13, 2025 |
| Downgrade | HALO | Wells Fargo | Overweight | Equal Weight | $58 | $62 | Oct. 7, 2024 |
| Downgrade | HALO | JP Morgan | Overweight | Neutral | $52 | $57 | Sept. 19, 2024 |
News
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Read More
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key growth drivers include the ENHANZE portfolio with new blockbuster drugs, a robust clinical pipeline, and next-gen delivery systems, ensuring sustained royalty growth and competitive advantage. Despite potential risks like the Keytruda SC litigation and pharma tariffs, Halozyme's strong balance sheet, rising free cash flow, and share buybacks boost EPS and shareholder value.
Read More
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025.
Read More
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Sadia Rahman - Wells Fargo Sean Laaman - Morgan Stanley Michael DiFiore - Evercore ISI Mitchell Kapoor - H.C. Wainwright Brendan Smith - TD Cowen David Risinger - Leerink Partners Operator Good afternoon.
Read More
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago.
Read More
Halozyme Therapeutics: Still Undervalued Ahead Of Earnings
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Positive
Halozyme Therapeutics, Inc. remains a buy due to its strong subscription-based business model, high growth, and undervaluation. HALO's robust product library, focused on drug delivery systems, positions it well to avoid sector issues and continue outperforming the market. The company has shown consistent revenue growth, high gross margins, and strong returns on investments, with a fair value estimated at $67.71.
Read More
Halozyme to Report First Quarter 2025 Financial and Operating Results
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m.
Read More
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
European Commission (EC) decision on marketing authorization application expected within approximately two months SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. …
Read More
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Published: April 07, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , April 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) marketing authorization of the subcutaneous (SC) formulation of RYBREVANT® (amivantamab), in combination with LAZCLUZE® (lazertinib), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. Additionally, it is approved as a monotherapy for adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after the failure of platinum-based therapy.
Read More
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue
Published: March 13, 2025 by: Investors Business Daily
Sentiment: Neutral
Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in 2024.
Read More
HALO vs. AMGN: Which Stock Is the Better Value Option?
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.26 1 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to …
Read More
About Halozyme Therapeutics, Inc. (HALO)
- IPO Date 2004-03-16
- Website https://www.halozyme.com
- Industry Biotechnology
- CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
- Employees 350